- Home
- EXG vs IDYA Comparison
EXG vs IDYA Comparison
Compare EXG & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXG
- IDYA
- Stock Information
- Founded
- EXG 2007
- IDYA 2015
- Country
- EXG United States
- IDYA United States
- Employees
- EXG N/A
- IDYA N/A
- Industry
- EXG Finance Companies
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- EXG Finance
- IDYA Health Care
- Exchange
- EXG Nasdaq
- IDYA Nasdaq
- Market Cap
- EXG 2.8B
- IDYA 2.3B
- IPO Year
- EXG N/A
- IDYA 2019
- Fundamental
- Price
- EXG $9.22
- IDYA $29.18
- Analyst Decision
- EXG
- IDYA Buy
- Analyst Count
- EXG 0
- IDYA 17
- Target Price
- EXG N/A
- IDYA $48.20
- AVG Volume (30 Days)
- EXG 533.2K
- IDYA 1.3M
- Earning Date
- EXG 01-01-0001
- IDYA 11-04-2025
- Dividend Yield
- EXG 8.27%
- IDYA N/A
- EPS Growth
- EXG N/A
- IDYA N/A
- EPS
- EXG N/A
- IDYA N/A
- Revenue
- EXG N/A
- IDYA $7,000,000.00
- Revenue This Year
- EXG N/A
- IDYA $90.17
- Revenue Next Year
- EXG N/A
- IDYA $219.42
- P/E Ratio
- EXG N/A
- IDYA N/A
- Revenue Growth
- EXG N/A
- IDYA N/A
- 52 Week Low
- EXG $6.78
- IDYA $13.45
- 52 Week High
- EXG $8.15
- IDYA $32.67
- Technical
- Relative Strength Index (RSI)
- EXG 59.16
- IDYA 60.13
- Support Level
- EXG $9.04
- IDYA $28.17
- Resistance Level
- EXG $9.19
- IDYA $31.07
- Average True Range (ATR)
- EXG 0.11
- IDYA 1.42
- MACD
- EXG -0.00
- IDYA 0.06
- Stochastic Oscillator
- EXG 80.65
- IDYA 60.76
About EXG Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.